Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Postmenopausal hormone therapy and coronary disease -- the truth of the matter

21.06.2007
With each new publication of coronary artery disease (CAD) data from the Women’s Health Initiative (WHI) study, the inevitable reaction is “Why on earth did the WHI investigators claim in 2002–2004 that postmenopausal hormone therapy has deleterious effects on the risk for CAD, when, from the beginning, they were aware of the importance of the age factor in this clinical scenario"”.

Women in the age group of 50–59 years who participated in the estrogen-alone arm of the WHI study were asked immediately after the early cessation of the trial to become part of an ancillary study – the WHI-CACS – which looked at the magnitude of coronary calcifications measured by ultra-fast coronary CT. Coronary calcium deposits develop as part of the atherosclerosis process and correlate well with findings of coronary angiography.

The results of WHI-CACS, now published in the New England Journal of Medicine [1] are very encouraging, since women who were randomized to the estrogen arm of the WHI had significantly smaller calcification scores than their counterparts in the placebo arm. The effect was recorded for all degrees of severity, with estrogen users having a 20–30% reduction in the likelihood of being categorized as having a mild to moderate increase in calcification scores (less than 100), and a more than 50% reduction in the likelihood of being categorized as advanced cases with calcification scores above 100. This study re-affirms what was actually known for many years, based on animal data and observational studies in women. Estrogen has a wide range of well-documented beneficial metabolic and vascular effects: it reduces the pace of accumulation of atherosclerosis, and decreases the risk of coronary events, provided that treatment is started early in the menopause. In addition, the CT in the WHI-CACS was performed at a mean age of 64.8 years, 7.4 years after randomization to the WHI trial, which suggests a new “safety margin” for age and duration of estrogen therapy, as women can be reassured that estrogen therapy is cardioprotective at least until age 65.

One of the main arguments that were raised at the time of publication of the preliminary data of the WHI 5 years ago, in attempt to explain the disconcordance between the results of previous large-scale, long-term, observational studies and the WHI cardiac data, was that randomized, placebo-controlled trials are always better and suffer less bias. With randomized trials being Level I evidence and observational trials considered Level II evidence, devaluation of good observational data became state-of-the-art. The recent post-hoc analyses from WHI show that, by the end of the day, the observational studies did give valuable information, which was comparable to that obtained by the randomized trials.

Even for the issue of coronary calcifications and hormone therapy, a literature search shows that “lower grade” encouraging clinical data were there for at least 10 years. Clearly, a real long-term, randomized, double-blind, placebo-controlled study on hormone therapy cannot be performed. The IMS therefore suggests that available long-term data from the Nurses’ Health Study and other major observational studies should be considered while making decisions on hormone therapy in clinical practice. Since most, if not all, women do not start hormone therapy at an old age, safety concerns on its possible adverse cardiac effects are actually invalid for the vast majority of hormone users. In fact, treatment seems to be associated with reduction of risk for coronary artery disease if initiated early.

Jean Wright | EurekAlert!
Further information:
http://www.imsociety.org/

More articles from Studies and Analyses:

nachricht Europe’s Demographic Future. Where the Regions Are Heading after a Decade of Crises
10.08.2017 | Berlin-Institut für Bevölkerung und Entwicklung

nachricht Scientists reveal source of human heartbeat in 3-D
07.08.2017 | University of Manchester

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Researchers devise microreactor to study formation of methane hydrate

23.08.2017 | Materials Sciences

ShAPEing the future of magnesium car parts

23.08.2017 | Automotive Engineering

New insights into the world of trypanosomes

23.08.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>